# Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

> **NCT00093613** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Oligodendroglioma
- Adult Giant Cell Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00093613
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2010-10
- **Final completion:** 2011-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093613, "Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00093613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*